These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11598414)

  • 1. Feasibility of oral topotecan in previously untreated patients with small-cell lung cancer ineligible for standard therapy.
    Eckardt JR
    Oncology; 2001; 61 Suppl 1():42-6. PubMed ID: 11598414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Future role of topotecan in the treatment of lung cancer.
    Schiller JH
    Oncology; 2001; 61 Suppl 1():55-9. PubMed ID: 11598416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: A North Central Cancer Treatment Group Study.
    Bryce AH; Mattar B; Hillman SL; Adjei AA; Kugler JW; Rowland K; Wender DB; Soori G; Perez EA; Jett JR
    Am J Clin Oncol; 2010 Aug; 33(4):353-7. PubMed ID: 19935387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I trial of a 5-day schedule of intravenous topotecan and etoposide in previously untreated patients with small-cell lung cancer.
    O'Neill P; Clark PI; Smith D; Marshall E; Hannigan K; Ross G
    Oncology; 2001; 61 Suppl 1():25-9. PubMed ID: 11598411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.
    Ardizzoni A; Manegold C; Debruyne C; Gaafar R; Buchholz E; Smit EF; Lianes P; ten Velde G; Bosquee L; Legrand C; Neumaier C; King K;
    Clin Cancer Res; 2003 Jan; 9(1):143-50. PubMed ID: 12538462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer.
    von Pawel J; Gatzemeier U; Pujol JL; Moreau L; Bildat S; Ranson M; Richardson G; Steppert C; Rivière A; Camlett I; Lane S; Ross G
    J Clin Oncol; 2001 Mar; 19(6):1743-9. PubMed ID: 11251005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914.
    Hesketh PJ; McCoy J; Dunphy FR; Bearden JD; Weiss GR; Giguere JK; Atkins JN; Dakhil SR; Kelly K; Crowley JJ; Gandara DR
    J Thorac Oncol; 2006 Nov; 1(9):991-5. PubMed ID: 17409984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New advances in lung cancer chemotherapy: topotecan and the role of topoisomerase I inhibitors.
    Huang CH; Treat J
    Oncology; 2001; 61 Suppl 1():14-24. PubMed ID: 11598410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
    Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.
    Jett JR; Hatfield AK; Hillman S; Bauman MD; Mailliard JA; Kugler JW; Morton RF; Marks RS; Levitt R
    Cancer; 2003 May; 97(10):2498-503. PubMed ID: 12733149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
    Eckardt JR; von Pawel J; Pujol JL; Papai Z; Quoix E; Ardizzoni A; Poulin R; Preston AJ; Dane G; Ross G
    J Clin Oncol; 2007 May; 25(15):2086-92. PubMed ID: 17513814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging role of weekly topotecan in recurrent small cell lung cancer.
    Eckardt JR
    Oncologist; 2004; 9 Suppl 6():25-32. PubMed ID: 15616147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.
    Paik PK; Rudin CM; Brown A; Rizvi NA; Takebe N; Travis W; James L; Ginsberg MS; Juergens R; Markus S; Tyson L; Subzwari S; Kris MG; Krug LM
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1079-85. PubMed ID: 20165849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer.
    Huber RM; Reck M; Gosse H; von Pawel J; Mezger J; Saal JG; Kleinschmidt R; Steppert C; Steppling H
    Eur Respir J; 2006 Jun; 27(6):1183-9. PubMed ID: 16481389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer.
    Quoix E; Breton JL; Gervais R; Wilson J; Schramel F; Cardenal F; Ross G; Preston A; Lymboura M; Mattson K
    Lung Cancer; 2005 Aug; 49(2):253-61. PubMed ID: 16022920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer.
    Spigel DR; Greco FA; Burris HA; Shipley DL; Clark BL; Whorf RC; Arrowsmith ER; Hainsworth JD
    Clin Lung Cancer; 2011 May; 12(3):187-91. PubMed ID: 21663862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is cisplatin required for the treatment of non-small-cell lung cancer? Experience and preliminary results of a phase I/II trial with topotecan and vinorelbine.
    Stupp R; Bodmer A; Duvoisin B; Bauer J; Perey L; Bakr M; Ketterer N; Leyvraz S
    Oncology; 2001; 61 Suppl 1():35-41. PubMed ID: 11598413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer.
    Agelaki S; Kontopodis E; Kotsakis A; Chandrinos V; Bompolaki I; Zafeiriou Z; Papadimitraki E; Stoltidis D; Kalbakis K; Georgoulias V
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):45-51. PubMed ID: 23604531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline.
    Cheng S; Evans WK; Stys-Norman D; Shepherd FA;
    J Thorac Oncol; 2007 Apr; 2(4):348-54. PubMed ID: 17409809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.